Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

An earlier report documented significant improvement in progression-free survival among patients with metastatic breast cancer treated with fulvestrant and a cyclin-dependent kinase inhibitor, ribociclib. With longer follow-up, it is clear that fulvestrant and ribociclib also prolong overall surviva...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-02, Vol.382 (6), p.514-524
Hauptverfasser:	Slamon, Dennis J, Neven, Patrick, Chia, Stephen, Fasching, Peter A, De Laurentiis, Michelino, Im, Seock-Ah, Petrakova, Katarina, Bianchi, Giulia V, Esteva, Francisco J, Martín, Miguel, Nusch, Arnd, Sonke, Gabe S, De la Cruz-Merino, Luis, Beck, J. Thaddeus, Pivot, Xavier, Sondhi, Manu, Wang, Yingbo, Chakravartty, Arunava, Rodriguez-Lorenc, Karen, Taran, Tetiana, Jerusalem, Guy
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aminopyridines - administration & dosage Aminopyridines - adverse effects Aminopyridines/administration & dosage/adverse effects Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms/drug therapy/mortality Cancer therapies Chemotherapy Cyclin-dependent kinases Drug Administration Schedule Endocrine therapy Epidermal growth factor ErbB-2 protein Female Fulvestrant Fulvestrant - administration & dosage Fulvestrant - adverse effects Fulvestrant/administration & dosage/adverse effects General & Internal Medicine Human health sciences Humans Hypotheses Hypothesis testing Kaplan-Meier Estimate Life Sciences & Biomedicine Medicine, General & Internal Middle Aged Oncologie oncology Patients Post-menopause Postmenopause Progression-Free Survival Purines - administration & dosage Purines - adverse effects Purines/administration & dosage/adverse effects Receptor, ErbB-2 Receptors, Estrogen Receptors, Progesterone Science & Technology Sciences de la santé humaine Statistical analysis Survival Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	An earlier report documented significant improvement in progression-free survival among patients with metastatic breast cancer treated with fulvestrant and a cyclin-dependent kinase inhibitor, ribociclib. With longer follow-up, it is clear that fulvestrant and ribociclib also prolong overall survival.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa1911149